Wet vs. Dry Macular Degeneration: Understanding the Difference
What Is the Difference Between Wet and Dry AMD?
Wet and dry AMD share the same underlying disease but differ in their mechanism of damage, speed of progression, and treatment approach.
Dry AMD, also called atrophic macular degeneration, accounts for roughly 85 to 90 percent of all AMD cases. It develops when small yellow protein deposits called drusen accumulate beneath the retina. Over time, these deposits cause the light-sensitive cells in the macula to thin and break down, leading to gradual central vision loss. Dry AMD progresses through three stages, early, intermediate, and late, and may take years before noticeably affecting your eyesight. The most advanced form of dry AMD is known as geographic atrophy, in which well-defined areas of retinal tissue waste away permanently.
Wet AMD, also called exudative or neovascular macular degeneration, accounts for about 10 to 15 percent of AMD cases. It occurs when abnormal blood vessels grow beneath the retina in a process called choroidal neovascularization. These fragile new vessels leak fluid and blood into the macula, causing rapid swelling and damage to the surrounding tissue. Because wet AMD can lead to significant central vision loss in a matter of weeks or months, prompt diagnosis and treatment are critical. Wet AMD is always considered an advanced stage of the disease, regardless of previous dry AMD staging.
In dry AMD, damage results from the slow deterioration of retinal pigment epithelium (RPE) cells and photoreceptors, with drusen buildup serving as the hallmark finding. In wet AMD, the primary damage comes from leaking and bleeding of abnormal blood vessels, which can cause scar tissue to form beneath the macula. Our retina specialists use optical coherence tomography (OCT) and fluorescein angiography to distinguish between the two forms and guide treatment decisions.
Can Dry AMD Convert to Wet AMD?
One of the most important aspects of living with dry AMD is understanding that it can progress to the wet form at any time, sometimes without warning.
Approximately 10 to 15 percent of people with dry AMD eventually develop wet AMD. The conversion occurs when the retina, deprived of adequate oxygen and nutrients due to RPE cell loss, triggers the growth of new abnormal blood vessels. This process can begin suddenly, and the shift from stable dry AMD to active wet AMD may happen over days to weeks.
Regular monitoring is essential for catching conversion early, when treatment is most effective. We recommend that patients with intermediate or advanced dry AMD check their vision at home using an Amsler grid to monitor for macular degeneration changes. Any new distortion, waviness, or blank spots on the grid should prompt an urgent evaluation. Routine dilated eye exams with OCT imaging allow our retina specialists to detect fluid or blood beneath the retina before you notice symptoms.
Certain factors increase the likelihood that dry AMD will progress to the wet form. These include having large or numerous drusen, pigmentary changes in the retina, a family history of wet AMD, and a history of smoking. Patients with advanced dry AMD in one eye are also at higher risk of developing wet AMD in the other eye.
Symptoms of Wet Macular Degeneration
Wet AMD often produces symptoms that are more sudden and noticeable than those of dry AMD, making awareness of these warning signs important for early intervention.
One of the earliest and most common symptoms of wet AMD is metamorphopsia, a condition in which straight lines appear wavy or bent. Doorframes, window blinds, and lines of text may look distorted. This occurs because fluid leaking from abnormal blood vessels causes the macula to swell unevenly, changing the way light is focused onto the retinal cells.
Wet AMD primarily affects central vision, the area you rely on for reading, driving, and recognizing faces. You may notice a blurry or dark spot in the center of your visual field that makes it difficult to see fine details. Peripheral (side) vision is typically preserved even in advanced cases, which is why AMD rarely leads to complete blindness.
Unlike dry AMD, which tends to progress gradually over years, wet AMD symptoms can appear within days. A sudden decrease in visual clarity or a new area of distortion warrants an urgent appointment. Early treatment within the first few weeks of symptom onset offers the best chance of preserving vision. You can read more about the full scope of this condition in our guide to wet age-related macular degeneration.
Some patients with wet AMD notice that colors appear less vivid or that they have trouble distinguishing objects from similarly colored backgrounds. Reading in dim lighting may become more challenging, and adapting from bright to dark environments may take longer than usual.
How Wet AMD Is Treated with Injections
Anti-VEGF therapy is the standard of care for wet AMD and has transformed outcomes for patients who once faced inevitable vision loss.
Vascular endothelial growth factor (VEGF) is a protein that signals the body to grow new blood vessels. In wet AMD, VEGF is overproduced, fueling the abnormal vessel growth beneath the retina. Anti-VEGF medications, delivered as intravitreal injections directly into the eye, block this protein and help stop vessel leakage and growth. Commonly used anti-VEGF agents include ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo), a bispecific antibody that targets both VEGF and angiopoietin-2 for potentially longer-lasting results.
Each injection appointment typically takes about 15 to 30 minutes. After numbing the eye with anesthetic drops, the medication is injected through the white part of the eye (sclera) into the vitreous cavity. Most patients report minimal discomfort, often describing only a brief sensation of pressure.
Treatment usually begins with a loading phase of monthly injections for the first three months. After that, the schedule may shift to a treat-and-extend protocol, where the interval between injections is gradually lengthened as long as the macula remains stable. Some patients eventually need injections every 8 to 16 weeks, while others require more frequent dosing depending on their response. Our retina specialists tailor each treatment plan based on OCT findings and clinical response.
Anti-VEGF therapy can stabilize vision in the majority of wet AMD patients, and about one-third experience measurable improvement. While the injections cannot reverse existing scar tissue or restore vision that has already been permanently lost, starting treatment promptly helps preserve as much functional vision as possible. Ongoing monitoring and consistent treatment adherence are essential for the best long-term outcomes. Researchers are also investigating gene therapy approaches that may one day reduce or eliminate the need for repeated injections.
Frequently Asked Questions
Increasing difficulty with reading, needing brighter light for close-up tasks, and a growing blurry area in your central vision can all indicate dry AMD is advancing. Your eye doctor may also detect worsening on imaging before you notice changes, which is why keeping scheduled follow-up appointments is important even when your vision feels stable.
Most patients start with monthly injections for three consecutive months and then transition to a treat-and-extend schedule. Depending on how the macula responds, injections may be needed every 4 to 16 weeks. Some patients can taper the frequency over time, while others require ongoing treatment to keep the disease controlled.
Optical coherence tomography provides detailed cross-sectional images of the retina, allowing your doctor to measure retinal thickness, detect fluid beneath or within the retinal layers, and track drusen changes over time. OCT is performed at nearly every monitoring visit and is the primary tool used to decide when injections are needed and whether treatment intervals can be extended. This same imaging technology also helps detect other macular conditions such as cystoid macular edema and macular holes requiring surgical repair.
The AREDS2 (Age-Related Eye Disease Study 2) formula has been shown to reduce the risk of progression from intermediate to advanced AMD by approximately 25 percent. The supplement contains lutein, zeaxanthin, vitamin C, vitamin E, zinc, and copper. A diet rich in leafy green vegetables, fish high in omega-3 fatty acids, and colorful fruits may further support macular health. You can read more about evidence-based nutritional strategies in our guide to macular degeneration vitamins and AREDS2 supplements.
Geographic atrophy (GA) is the advanced stage of dry AMD, characterized by well-defined areas of complete retinal pigment epithelium and photoreceptor loss. These areas expand over time, creating permanent blind spots in the central visual field. Two complement inhibitor medications, Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), were FDA-approved in 2023 specifically to slow GA progression. You can learn more about these therapies in our overview of new AMD treatments including Syfovre and Izervay.
Syfovre and Izervay are the first FDA-approved treatments for geographic atrophy, delivered as intravitreal injections on a monthly or bimonthly schedule. Clinical trials showed these complement inhibitors can slow GA lesion growth by approximately 14 to 35 percent over one to two years, though they do not restore vision already lost. Research into additional therapies, including gene therapy and other novel targets, continues to advance rapidly and offers hope for future improvements in dry AMD care.
What our Patients say
4.8
Reviews
(3,408)